Immunogenicity and Reactogenicity of 10-valent Pneumococcal Conjugate Vaccine (PCV10) in Children Aged 12-59 Months

Trial Profile

Immunogenicity and Reactogenicity of 10-valent Pneumococcal Conjugate Vaccine (PCV10) in Children Aged 12-59 Months

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; DTaP vaccine; Hepatitis A vaccine inactivated
  • Indications Diphtheria; Hepatitis A; Pertussis; Pneumococcal infections; Tetanus
  • Focus Pharmacodynamics
  • Acronyms PRISM
  • Most Recent Events

    • 20 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 04 Dec 2015 Planned End Date changed from 1 Mar 2011 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 23 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top